Post-marketing Safety Study of Autoimmune Diseases Following Cervarix Vaccination in Females Aged 9-25 Years in the US

Trial Profile

Post-marketing Safety Study of Autoimmune Diseases Following Cervarix Vaccination in Females Aged 9-25 Years in the US

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Aug 2014

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 31 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 30 Aug 2013 Planned end date changed from 1 Dec 2050 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 28 Sep 2012 Planned end date changed from 1 Oct 2014 to 1 Dec 2050 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top